On the other hand, Ocoxin reduces fibroblast-mediated tumor progression by means of overcoming resistance against targeted therapy with the BRAF inhibitor and impairing fibroblast-mediated tumor cell migration. The gene discussed is BRAF; the disease is neoplasm.